Research graph
References from Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study. Local targets link to admitted publications; unresolved targets remain external evidence.
M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy
10.1056/nejmoa0810457 · 2009 · External reference
Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy
10.1371/journal.pone.0062151 · 2013 · External reference
Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy
10.1056/nejmoa1409354 · 2014 · External reference
Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy
10.1681/asn.2013040430 · 2014 · External reference
Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy
10.2215/cjn.10471013 · 2014 · External reference
Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy
10.2215/cjn.07210810 · 2011 · External reference
Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy
10.1038/ki.2012.486 · 2013 · External reference
Identification of group X secretory phospholipase A(2) as a natural ligand for mouse phospholipase A(2) receptor.
10.1016/s0014-5793(00)01848-2 · 2000 · External reference
Presence of the M-type sPLA(2) receptor on neutrophils and its role in elastase release and adhesion.
10.1152/ajpcell.00608.2001 · 2002 · External reference
Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous ne- phropathy
10.1681/asn.2013121315 · 2015 · External reference
Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy
10.1681/asn.2014050502 · 2015 · External reference
Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy
10.1681/asn.2014111061 · 2016 · External reference
Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy
10.1681/asn.2017070734 · 2018 · External reference
Clinical relevance of domain-specific phospholipase A2 receptor1 antibody levels
10.1681/asn.2019030273 · 2020 · External reference
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
2021 · External reference
High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy
10.2215/cjn.11791018 · 2019 · External reference
Does epitope spreading influence responsiveness to rituximab in PLA2R-associated membranous nephropathy
10.2215/cjn.07300619 · 2019 · External reference
Improvement of idiopathic membranous nephropa- thy diagnosis with ultrasensitive quantitative detection of anti-phospholipase A2 receptor
10.1016/j.jaci.2016.10.020 · 2017 · External reference
Phospholipase A2 receptor antibody IgG4 subclass improves sensitivity and specificity in the diagnosis of idiopathic membranous nephropathy
10.1159/000500456 · 2019 · External reference
A PLA2R-IgG4 antibody-based predictive model for assessing risk stratification of idiopathic membranous nephropathy
2021 · External reference
PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study
10.7717/peerj.14193 · 2022 · External reference
Quantitative detection of anti-PLA2R antibodies targeting different epitopes and its clinical application in primary membranous nephropathy
10.1515/cclm-2022-0720 · 2022 · External reference
Rituximab or cyclosporine in the treatment of membranous nephropathy
10.1056/nejmoa1814427 · 2019 · External reference
Rituximab in idiopathic membranous nephropathy
10.1681/asn.2012020181 · 2012 · External reference
Treatment of nephrotic idiopathic membranous nephropathy with monthly i.v. pulse cyclophosphamide and oral steroids: a single centre’s retrospective study
10.1111/j.1440-1797.2010.01427.x · 2011 · External reference
Substitution of Oral for Intravenous Cyclophosphamide in Membranous Nephropathy.
10.34067/kid.0002802020 · 2020 · External reference
Intravenous cyclophosphamide as an alternative to the oral cyclophosphamide modified Ponticelli regimen for high-risk PLA2R-positive membranous nephropathy.
10.1007/s40620-022-01426-6 · 2023 · External reference
Rituximab: emerging treatment strategies of immune-mediated glomerular disease
10.1586/eci.12.26 · 2012 · External reference
B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab
10.1016/j.kint.2017.01.012 · 2017 · External reference
Immunology of idiopathic nephrotic syndrome
10.1007/s00467-017-3677-5 · 2018 · External reference
Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial
10.1681/asn.2020071091 · 2021 · External reference
Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-incident and relapsing primary membranous nephropathy
10.1111/nep.12955 · 2018 · External reference
Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy
10.1080/0886022x.2022.2033265 · 2022 · External reference
Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy
10.1681/asn.2014070640 · 2015 · External reference
Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy
10.1681/asn.2009080861 · 2010 · External reference
Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy
10.1038/ki.2015.310 · 2015 · External reference
Anti-PLA2R1 Antibodies as Prognostic Biomarker in Membranous Nephropathy
10.1016/j.ekir.2021.04.002 · 2021 · External reference
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy
10.1016/j.kint.2020.10.014 · 2021 · External reference
